{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T15:50:40Z","timestamp":1790005840877,"version":"4.0.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2014,1,25]],"date-time":"2014-01-25T00:00:00Z","timestamp":1390608000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2014,1,25]],"date-time":"2014-01-25T00:00:00Z","timestamp":1390608000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1007\/s10637-014-0066-9","type":"journal-article","created":{"date-parts":[[2014,1,24]],"date-time":"2014-01-24T08:58:53Z","timestamp":1390553933000},"page":"526-534","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":58,"title":["Phase II trial of vorinostat in advanced melanoma"],"prefix":"10.1007","volume":"32","author":[{"given":"N. B.","family":"Haas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Quirt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Hotte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"McWhirter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Polintan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Litwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. D.","family":"Adams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"McBryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. P.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"vonMehren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. K.","family":"Alpaugh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Zweibel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Oza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,1,25]]},"reference":[{"key":"66_CR1","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1038\/nrc3130","volume":"11","author":"SB Baylin","year":"2011","unstructured":"Baylin SB, Jones PA (2011) A decade of exploring the cancer epigenome\u2014biological and translational implications. Nature reviews Cancer 11:726\u2013734","journal-title":"Nature reviews Cancer"},{"key":"66_CR2","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.2174\/0929867033456657","volume":"10","author":"J Arts","year":"2003","unstructured":"Arts J, de Schepper S, Van Emelen K (2003) Histone deacetylase inhibitors: from chromatin remodeling to experimental cancer therapeutics. Curr Med Chem 10:2343\u20132350","journal-title":"Curr Med Chem"},{"key":"66_CR3","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1038\/35106079","volume":"1","author":"P Marks","year":"2001","unstructured":"Marks P, Rifkind RA, Richon VM et al (2001) Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 1:194\u2013202","journal-title":"Nat Rev Cancer"},{"key":"66_CR4","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1517\/13543784.11.12.1695","volume":"11","author":"WK Kelly","year":"2002","unstructured":"Kelly WK, O\u2019Connor OA, Marks PA (2002) Histone deacetylase inhibitors: from target to clinical trials. Expert Opin Investig Drugs 11:1695\u20131713","journal-title":"Expert Opin Investig Drugs."},{"issue":"4","key":"66_CR5","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1016\/j.bbrc.2004.01.149","volume":"315","author":"SH Kim","year":"2004","unstructured":"Kim SH, Ahn S, Han JW et al (2004) Apicidin is a histone deacetylase inhibitor with anti-invasive and anti-angiogenic potentials. Biochem Biophys Res Commun 315(4):964\u2013970","journal-title":"Biochem Biophys Res Commun"},{"issue":"8","key":"66_CR6","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1016\/S0006-2952(03)00509-4","volume":"66","author":"XD Zhang","year":"2003","unstructured":"Zhang XD, Gillespie SK, Borrow JM, Hersey P (2003) The histone deacetylase inhibitor suberic bishydroxamate: a potential sensitizer of melanoma to TNF-related apoptosis-inducing ligand (TRAIL) induced apoptosis. Biochem Pharmacol 66(8):1537\u20131545","journal-title":"Biochem Pharmacol"},{"issue":"6","key":"66_CR7","doi-asserted-by":"publisher","first-page":"2390","DOI":"10.1167\/iovs.02-1052","volume":"44","author":"DD Klisovic","year":"2003","unstructured":"Klisovic DD, Katz SE, Effron D, Klisovic MI, Wickham J, Parthun MR, Guimond M, Marcucci G (2003) Depsipeptide (FR901228) inhibits proliferation and induces apoptosis in primary and metastatic human uveal melanoma cell lines. Invest Ophthalmol Vis Sci 44(6):2390\u20132398","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"1","key":"66_CR8","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/S0304-3835(00)00676-5","volume":"163","author":"K Demary","year":"2001","unstructured":"Demary K, Wong L, Spanjaard RA et al (2001) Effects of retinoic acid and sodium butyrate on gene expression, histone acetylation and inhibition of proliferation of melanoma cells. Cancer Lett 163(1):103\u2013107","journal-title":"Cancer Lett"},{"issue":"3","key":"66_CR9","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/sj.cgt.7700551","volume":"10","author":"S Yamamoto","year":"2003","unstructured":"Yamamoto S, Yamano T, Tanaka M et al (2003) A novel combination of suicide gene therapy and histone deacetylase inhibitor for treatment of malignant melanoma. Cancer Gene Ther 10(3):179\u2013186","journal-title":"Cancer Gene Ther"},{"issue":"22","key":"66_CR10","doi-asserted-by":"publisher","first-page":"8693","DOI":"10.1158\/0008-5472.CAN-09-1456","volume":"69","author":"DD Vo","year":"2009","unstructured":"Vo DD, Prins RM, Begley JL et al (2009) Enhanced antitumor activity induced by adoptive T-cell transfer and adjunctive use of the histone deacetylase inhibitor LAQ824. Cancer Res 69(22):8693\u20138699","journal-title":"Cancer Res"},{"issue":"7","key":"66_CR11","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1038\/sj.bjc.6605293","volume":"101","author":"PN Munster","year":"2009","unstructured":"Munster PN, Marchion D, Thomas S et al (2009) Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker. Br J Cancer 101(7):1044\u20131050","journal-title":"Br J Cancer"},{"issue":"1","key":"66_CR12","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1158\/1535-7163.MCT-06-0125","volume":"6","author":"Y Kato","year":"2007","unstructured":"Kato Y, Salumbides BC, Wang XF et al (2007) Antitumor effect of the histone deacetylase inhibitor LAQ824 in combination with 13-cis-retinoic acid in human malignant melanoma. Mol Cancer Ther 6(1):70\u201381","journal-title":"Mol Cancer Ther"},{"key":"66_CR13","first-page":"3578","volume":"9","author":"WK Kelly","year":"2003","unstructured":"Kelly WK, Richon VM, O\u2019Connor O et al (2003) Phase I clinical trial of histone deacetylase inhibitor: Suberoylanilide hydroxamic acid administered intravenously. Clin Cancer Res 9:3578\u20133588","journal-title":"Clin Cancer Res."},{"issue":"3","key":"66_CR14","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1128\/MCB.01639-06","volume":"27","author":"R Zhang","year":"2007","unstructured":"Zhang R, Liu ST, Chen W, Bonner M, Pehrson J, Yen TJ, Adams PD (2007) HP1 proteins are essential for a dynamic nuclear response that rescues the function of perturbed heterochromatin in primary human cells. Mol Cell Biol 27(3):949\u2013962","journal-title":"Mol Cell Biol"},{"issue":"7","key":"66_CR15","doi-asserted-by":"publisher","first-page":"784","DOI":"10.4161\/cc.6.7.4079","volume":"6","author":"R Zhang","year":"2007","unstructured":"Zhang R, Adams PD (2007) Heterochromatin and its relationship to cell senescence and cancer therapy. Cell Cycle 6(7):784\u2013789, Epub 2007 Apr 27. Review","journal-title":"Cell Cycle"},{"issue":"4","key":"66_CR16","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/S1535-6108(03)00079-5","volume":"3","author":"D Bergamaschi","year":"2003","unstructured":"Bergamaschi D, Gasco M, Hiller L, Sullivan A, Syed N, Trigiante G, Yulug I, Merlano M, Numico G, Comino A, Attard M, Reelfs O, Gusterson B, Bell AK, Heath V, Tavassoli M, Farrell PJ, Smith P, Lu X, Crook T (2003) p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell 3(4):387\u2013402","journal-title":"Cancer Cell"},{"issue":"6","key":"66_CR17","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1046\/j.1523-1747.2003.12648.x","volume":"121","author":"H Shen","year":"2003","unstructured":"Shen H, Liu Z, Strom SS, Spitz MR, Lee JE, Gershenwald JE, Ross MI, Mansfield PF, Duvic M, Ananthaswamy HN, Wei Q (2003) p53 codon 72 Arg homozygotes are associated with an increased risk of cutaneous melanoma. J Invest Dermatol 121(6):1510\u20131514","journal-title":"J Invest Dermatol"},{"issue":"3","key":"66_CR18","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/ng1093","volume":"33","author":"P Dumont","year":"2003","unstructured":"Dumont P, Leu JI, 3rd Della Pietra AC, George DL, Murphy M (2003) The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 33(3):357\u2013365","journal-title":"Nat Genet"},{"issue":"20","key":"66_CR19","doi-asserted-by":"publisher","first-page":"3172","DOI":"10.1038\/sj.onc.1206457","volume":"22","author":"M Streit","year":"2003","unstructured":"Streit M, Detmar M (2003) Angiogenesis, lymphangiogenesis, and melanoma metastasis. Oncogene 22(20):3172\u20133179","journal-title":"Oncogene"},{"issue":"3","key":"66_CR20","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1006\/bbrc.1993.1106","volume":"190","author":"H Gitay-Goren","year":"1993","unstructured":"Gitay-Goren H, Halaban R, Neufeld G (1993) Human melanoma cells but not normal melanocytes express vascular endothelial growth factor receptors. Biochem Biophys Res Commun 190(3):702\u2013708","journal-title":"Biochem Biophys Res Commun"},{"issue":"6","key":"66_CR21","first-page":"547","volume":"12","author":"E Lazar-Molnar","year":"2000","unstructured":"Lazar-Molnar E, Hegyesi H, Toth S, Falus A (2000) Autocrine and paracrine regulation by cytokines and growth factors in melanoma. Cytokine+ 12(6):547\u2013554","journal-title":"Cytokine+"},{"issue":"5","key":"66_CR22","doi-asserted-by":"crossref","first-page":"241","DOI":"10.3727\/096504001108747738","volume":"12","author":"D Dreau","year":"2000","unstructured":"Dreau D, Foster M, Hogg M, Swiggett J, Holder WD, White RL (2000) Angiogenic and immune parameters during recombinant interferon-alpha2b adjuvant treatment in patients with melanoma. Oncol Res 12(5):241\u2013251","journal-title":"Oncol Res"},{"issue":"3","key":"66_CR23","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1038\/sj.onc.1205108","volume":"21","author":"CF Deroanne","year":"2002","unstructured":"Deroanne CF, Bonjean K, Servotte S, Devy L, Colige A, Clausse N, Blacher S, Verdin E, Foidart JM, Nusgens BV, Castronovo V (2002) Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling. Oncogene 21(3):427\u2013436","journal-title":"Oncogene"},{"issue":"3","key":"66_CR24","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.bbrc.2004.02.105","volume":"316","author":"D Zgouras","year":"2004","unstructured":"Zgouras D, Becker U, Loitsch S, Stein J (2004) Modulation of angiogenesis-related protein synthesis by valproic acid. Biochem Biophys Res Commun 316(3):693\u2013697","journal-title":"Biochem Biophys Res Commun"},{"issue":"4","key":"66_CR25","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/86507","volume":"7","author":"MS Kim","year":"2001","unstructured":"Kim MS, Kwon HJ, Lee YM, Baek JH, Jang JE, Lee SW, Moon EJ, Kim HS, Lee SK, Chung HY, Kim CW, Kim KW (2001) Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat Med 7(4):437\u2013443","journal-title":"Nat Med"},{"issue":"3","key":"66_CR26","first-page":"205","volume":"92","author":"Response Evaluation Criteria in Solid Tumors","year":"2000","unstructured":"Response Evaluation Criteria in Solid Tumors (RECIST) Committee. JNCI 92(3):205\u2013216, 2000","journal-title":"RECIST) Committee. JNCI"},{"issue":"Suppl 1","key":"66_CR27","first-page":"S11","volume":"6","author":"MB Atkins","year":"2000","unstructured":"Atkins MB, Kunkel L, Sznol M, Rosenberg SA (2000) High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer J Sci Am 6(Suppl 1):S11\u2013S14","journal-title":"Cancer J Sci Am."},{"issue":"8","key":"66_CR28","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1056\/NEJMoa1112302","volume":"366","author":"JA Sosman","year":"2012","unstructured":"Sosman JA, Kim KB, Schuchter L et al (2012) Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 366(8):707\u2013714","journal-title":"N Engl J Med"},{"issue":"2","key":"66_CR29","doi-asserted-by":"publisher","first-page":"286","DOI":"10.4161\/cc.11.2.18707","volume":"11","author":"P Hou","year":"2012","unstructured":"Hou P, Liu D, Dong J, Xing M (2012) The BRAF(V600E) causes widespread alterations in gene methylation in the genome of melanoma cells. Cell Cycle 11(2):286\u2013295","journal-title":"Cell Cycle"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-014-0066-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-014-0066-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-014-0066-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-014-0066-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T04:48:42Z","timestamp":1678510122000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-014-0066-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1,25]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["66"],"URL":"https:\/\/doi.org\/10.1007\/s10637-014-0066-9","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,1,25]]},"assertion":[{"value":"3 December 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2014","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2014","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}